• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[The EMBARK trial: The use of enzalutamide in biochemically recurrent prostate cancer after primary therapy].

作者信息

Shelan Mohamed, Mathier Etienne, Aebersold Daniel M, Wiegel Thomas

机构信息

Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, 3010, Bern, Schweiz.

Department of Radiation Oncology, University Hospital Ulm, Ulm, Deutschland.

出版信息

Strahlenther Onkol. 2025 Jun;201(6):666-668. doi: 10.1007/s00066-025-02371-6. Epub 2025 Feb 21.

DOI:10.1007/s00066-025-02371-6
PMID:39982503
Abstract
摘要

相似文献

1
[The EMBARK trial: The use of enzalutamide in biochemically recurrent prostate cancer after primary therapy].[EMBARK试验：恩杂鲁胺在初始治疗后生化复发前列腺癌中的应用]
Strahlenther Onkol. 2025 Jun;201(6):666-668. doi: 10.1007/s00066-025-02371-6. Epub 2025 Feb 21.
2
Cost-effectiveness of enzalutamide with androgen-deprivation therapy (ADT) versus ADT alone for the treatment of high-risk biochemically recurrent non-metastatic castration-sensitive prostate cancer in Canada.恩杂鲁胺联合雄激素剥夺疗法（ADT）与单纯ADT治疗加拿大高危生化复发非转移性去势敏感性前列腺癌的成本效益
J Med Econ. 2025 Dec;28(1):766-777. doi: 10.1080/13696998.2025.2503660. Epub 2025 May 23.
3
Enzalutamide in biochemically recurrent prostate cancer: key findings from the EMBARK study.恩杂鲁胺用于生化复发前列腺癌：EMBARK研究的主要发现
Future Oncol. 2025 Apr;21(10):1151-1156. doi: 10.1080/14796694.2025.2479331. Epub 2025 Mar 27.
4
Enzalutamide in biochemically recurrent prostate cancer: design and rationale of the EMBARK study.恩杂鲁胺用于生化复发前列腺癌：EMBARK研究的设计与原理
Future Oncol. 2025 Apr;21(10):1145-1149. doi: 10.1080/14796694.2025.2478786. Epub 2025 Mar 25.
5
LBA02-09 EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-risk Biochemically Recurrent Prostate Cancer.LBA02-09：EMBARK 研究：恩扎卢胺或安慰剂联合醋酸亮丙瑞林与恩扎卢胺单药治疗高危生化复发前列腺癌的 3 期随机研究。
J Urol. 2023 Jul;210(1):224-226. doi: 10.1097/JU.0000000000003518. Epub 2023 May 2.
6
Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer.恩杂鲁胺治疗前列腺癌生化复发的生活质量研究
NEJM Evid. 2023 Dec;2(12):EVIDoa2300251. doi: 10.1056/EVIDoa2300251. Epub 2023 Oct 22.
7
Enzalutamide in Men With High-Risk Biochemically Recurrent Prostate Cancer: Rationale and Treatment Considerations From EMBARK.恩杂鲁胺用于高危生化复发前列腺癌男性患者：来自EMBARK研究的理论依据和治疗考量
J Urol. 2025 Jan;213(1):110-113. doi: 10.1097/JU.0000000000004228. Epub 2024 Sep 3.
8
Enzalutamide in patients with high-risk biochemically recurrent prostate cancer according to the European Association of Urology definition: a post hoc analysis of EMBARK.根据欧洲泌尿外科学会定义，恩杂鲁胺用于高危生化复发前列腺癌患者：EMBARK研究的事后分析
Prostate Cancer Prostatic Dis. 2025 Mar 26. doi: 10.1038/s41391-025-00959-8.
9
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.恩杂鲁胺治疗生化复发前列腺癌的疗效改善。
N Engl J Med. 2023 Oct 19;389(16):1453-1465. doi: 10.1056/NEJMoa2303974.
10
Enzalutamide Monotherapy in the EMBARK Trial Should Be Practice-changing and Existing Data Suggest How to Mitigate Toxicity.在 EMBARK 试验中，恩杂鲁胺单药治疗应该改变实践，并且现有数据提示如何减轻毒性。
Eur Urol Oncol. 2024 Oct;7(5):971-972. doi: 10.1016/j.euo.2024.06.001. Epub 2024 Jun 29.

本文引用的文献

1
Reply to M. Kamrava and F. Montorsi et al.对M. 卡姆拉瓦和F. 蒙托西等人的回复
J Clin Oncol. 2024 Sep 17:JCO2401345. doi: 10.1200/JCO-24-01345.
2
Delayed definitive management of localized prostate cancer: what do we know?局限性前列腺癌的延迟确定性治疗：我们了解什么？
Prostate Cancer Prostatic Dis. 2025 Jun;28(2):280-287. doi: 10.1038/s41391-024-00876-2. Epub 2024 Aug 11.
3
The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies.
转移性前列腺癌患者的转移灶定向治疗的疗效和安全性：前瞻性研究的系统评价和荟萃分析。
Eur Urol. 2024 Feb;85(2):125-138. doi: 10.1016/j.eururo.2023.10.012. Epub 2023 Nov 7.
4
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.恩杂鲁胺治疗生化复发前列腺癌的疗效改善。
N Engl J Med. 2023 Oct 19;389(16):1453-1465. doi: 10.1056/NEJMoa2303974.
5
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.醋酸阿比特龙和泼尼松与或不与恩扎卢胺用于高危非转移性前列腺癌：来自 STAMPEDE 平台方案两项随机对照 3 期试验主要结果的荟萃分析。
Lancet. 2022 Jan 29;399(10323):447-460. doi: 10.1016/S0140-6736(21)02437-5. Epub 2021 Dec 23.
6
Targeting Oligometastasis with Stereotactic Ablative Radiation Therapy or Surgery in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review of Prospective Clinical Trials.立体定向消融放疗或手术治疗转移性激素敏感前列腺癌寡转移灶：前瞻性临床试验的系统评价。
Eur Urol Oncol. 2020 Oct;3(5):582-593. doi: 10.1016/j.euo.2020.07.004. Epub 2020 Sep 3.
7
Consensus on molecular imaging and theranostics in prostate cancer.前列腺癌分子影像与治疗学共识。
Lancet Oncol. 2018 Dec;19(12):e696-e708. doi: 10.1016/S1470-2045(18)30604-1.
8
Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.雄激素剥夺治疗时机对 PSA 升高的前列腺癌患者的影响（TROG 03.06 和 VCOG PR 01-03 [TOAD]）：一项随机、多中心、非盲、3 期临床试验。
Lancet Oncol. 2016 Jun;17(6):727-737. doi: 10.1016/S1470-2045(16)00107-8. Epub 2016 May 4.